Not yet recruiting
RIVKAL clinical trial for the first-in-human administration of BIM2b in participants with Glioblastoma
2023-508662-15-00· Phase 1· Beta Innov· Source
Not yet recruiting
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source
Contact: Pierre ARNAUTOU
Not yet recruiting
Prospective evaluation of response to treatment by analysis of measurable residual disease in younger adult patients (18-60 years) with acute myeloid leukemia (AML). The Backbone InterGroup (BIG)-2 umbrella trial from the Acute Leukemia French Intergroup (ALFA, FILO) - BIG2
2026-525759-96-00· Phase 4· Centre Hospitalier Universitaire De Toulouse· Source
Not yet recruiting
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
2024-516570-30-00· Phase 2· Centre Hospitalier De Versailles· Source
Recruiting
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
NCT07556159· Phase 4· Sanofi· Source
Not yet recruiting
FILO-AML-01-MIVONU
A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.
2025-521322-14-00· Phase 2· French Innovative Leukemia Organization· Source
Recruiting
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
NCT06918002· Phase 3· Intergroupe Francophone du Myelome· Source
Active, not recruiting
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
NCT06931704· Phase 2· Nantes University Hospital· Source
Recruiting
IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as post transplantation maintenance therapy in patients with newly-diagnosed myeloma
2024-517325-43-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
NCT06471465· Phase 3· Institut Cancerologie de l'Ouest· Source
Active, not recruiting
TocilizuMab discontinuAtion in GIant Cell Arteritis
2023-505515-21-00· Phase 3· Centre Hospitalier Universitaire De Dijon· Source
Recruiting
Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study
NCT05895344· Centre Francois Baclesse· Source
Contact: Damien RICARD, PhD
Recruiting
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
NCT06022003· Phase 2· French Innovative Leukemia Organisation· Source
Recruiting
Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets
NCT05627375· Phase 3· Centre Hospitalier Universitaire de Saint Etienne· Source
Recruiting
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
NCT05907057· Phase 3· Servier Affaires Médicales· Source
Active, not recruiting
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
NCT05199051· Phase 2· Centre Antoine Lacassagne· Source
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT05255302· Phase 2/3· Intergroupe Francophone de Cancerologie Thoracique· Source
Active, not recruiting
MInimal Residual Disease Adapted Strategy
NCT04934475· Phase 3· Intergroupe Francophone du Myelome· Source
Recruiting
Study for the Quantification in Ecological Conditions of Sensorimotor and Dysexecutive Disorders in Cerebral Palsy Patients
NCT05017051· Direction Centrale du Service de Santé des Armées· Source
Contact: Flavie BOMPAIRE, MD
Active, not recruiting
Holter of Movement in Patients with Multiple Sclerosis in Uncontrolled Environment.
NCT04882891· Centre Hospitalier Universitaire de Liege· Source
Active, not recruiting
Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.
NCT04144387· Intergroupe Francophone du Myelome· Source
Active, not recruiting
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT03977194· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source
Completed
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
NCT03895671· Phase 2· Versailles Hospital· Source
Active, not recruiting
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00005584· Phase 3· European Organisation for Research and Treatment of Cancer - EORTC· Source